Liver-targeted radioactive drug for GI or pancreas NET liver spread
Part of Cancer clinical trials.
This study tests a way to deliver a radioactive “somatostatin-type” medicine directly into the liver artery to treat liver-dominant spread of neuroendocrine tumors (NETs). It may help shrink or control liver metastases after standard treatment has not worked enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a proven neuroendocrine tumor from the stomach/intestines or pancreas (well differentiated)
- Your cancer has grown or invaded the liver, and liver metastases are the main problem; surgery is not an option after your last treatment
- You have already completed 4 treatment cycles of LUTATHERA® (a somatostatin-type radioactive therapy)
- Your body is strong enough for treatment (ECOG 0 to 2) and your kidney and liver blood tests meet limits
- Your blood counts after LUTATHERA® are adequate (hemoglobin, neutrophils, and platelets are not too low)
- You can use effective birth control (if you can become pregnant) and you are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This Phase 1 study tests how well Lutathera combined with ASTX727 can treat neuroendocrine tumors. It looks mainly at whether the combination can be given safely and effectively for people whose tumors have grown or not tolerated standard first treatment.
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
Hear when a new Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.